论文部分内容阅读
目的研究以7种人非霍奇金淋巴瘤(NHL)细胞株为实验对象,以细胞抑制率、半数抑制浓度(IC50)为指标,研究硼替佐米(Bortezomib,BZM)对7种淋巴瘤细胞株的体外敏感状况,从而为临床用药提供实验理论依据。方法 MTT法检测细胞抑制率,并计算半数抑制浓度IC50值。结果 7种淋巴瘤细胞株均对BZM敏感,但BZM对不同淋巴瘤细胞株的敏感性存在差异。结论 BZM对B细胞型、T细胞型淋巴瘤细胞株均敏感。
Objective To study the effects of Bortezomib (BZM) against seven kinds of human non-Hodgkin’s lymphoma (NHL) cell lines on seven kinds of lymphoma cells Strain in vitro susceptible conditions, thus providing experimental theoretical basis for clinical drug use. Methods MTT method was used to detect the inhibition rate of cells, and the IC50 value of half inhibitory concentration was calculated. Results All seven lymphoma cell lines were sensitive to BZM, but the sensitivity of BZM to different lymphoma cell lines was different. Conclusion BZM is sensitive to both B-cell and T-cell lymphoma cell lines.